Date: 2014-04-14
Type of information: Grant
Company: The EFFIMAB consortium (Effimune, PX’Therapeutics, The Nantes Centre for Research in Transplantation and Immunology (CRTI/INSERM UMR 1064) and the Institute for Transplantation-Urology-Nephrology (ITUN), based in Nantes, the University Institute of Hematology (INSERM-UMR944) of the St Louis Hospital in Paris, the Paris Public Welfare Hospital (Assistance Publique–Hôpitaux de Paris), and the Lille Regional University Hospital Centre (CHRU de Lille)
Investors: Bpifrance (France)
Amount: €9.5 million
Funding type: subvention and refundable aids
Planned used: * On April 14, 2014, Effimune has announced that it has just signed a financing agreement with the Public Investment Bank (Bpifrance), in the framework of the aid to Strategic Industrial Innovation programme (ISI). The agreement concerns the EFFIMAB project to develop a new generation of immunomodulatory antibodies targeting the interleukin-7 receptor (IL7R) in order to treat ulcerative colitis and T-cell acute lymphoblastic leukaemia. “The EFFIMAB consortium is capitalising on the significant expertise existing in France in immunotherapy in cancer and autoimmune diseases and on the industrial know-how ofPX’Therapeutics” affirmed Maryvonne Hiance, President of Effimune, adding “Monoclonal antibodies are one of a number of biopharmaceutical, an emerging class of treatment. Their major therapeutic interest lies in their targeted effect which increases their effectiveness and reduces the incidence of side-effects”. The EFFIMAB consortium will manage the development of an industrial manufacturing procedure and phases I and II of the clinical development of the drug candidate. Of the overall budget of €20M, Bpifrance is providing €9.5M in subsidies and refundable aids.
Others:
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Cancer - Oncology
